Efficacy and Safety of Cerivastatin, 0.2 mg and 0.4 mg, in Patients with Primary Hypercholesterolemia: a Multinational, Randomised, Double-blind Study
Authors:
- Leiv OseLOLeiv Ose
- Olavi LuurilaOLOlavi Luurila
- J. ErikssonJEJ. Eriksson
- Anders OlssonAOAnders Olsson
- Bengt WidgrenBWBengt Widgren
- on behalf of the Cerivastatin StudyOSon behalf of the Cerivastatin Study
- 1 January 1999
- journal article
- clinical trial
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 15 (3) , 228-240
Abstract
SummaryElevated serum cholesterol level is a key risk factor for cardiovascular morbidity and mortality. Cerivastatin is a highly effective lipid-lowering agent currently licensed at doses of 0.1, 0.2, 0.3 and 0.4 mg.This was a multicentre, randomised, double-blind, parallel-group study comparing the efficacy and safety of cerivastatin OAmglday with that of cerivastatin 0.2 mg/day in patients with primary hypercholesterolemia. There was a six-week placebo run-in phase followed by a 24-week active treatment phase. A total of 494 patients were randomised to receive cerivastatin 0.4mg (n = 332) or 0.2mg (n = 162). Per-protocol (PP) analysis revealed that mean low-density lipoprotein cholesterol (LDL-C) level decreased by 38.4 ± 0.7% from baseline in the 0.4 mg group, compared with a decrease of 31.5 ± 0.9% in the 0.2mg group (p < 0.0001). There was a significant gender difference in the 0.4 mg group: LDL-C decreased by 44.4 ± 8.9% in women, compared with a decrease of 37.0 ± 0.9% in men (p < 0.046). In the P...Keywords
This publication has 9 references indexed in Scilit:
- INTERNATIONAL MULTICENTRE COMPARISON OF CERIVASTATIN WITH PLACEBO AND SIMVASTATIN FOR THE TREATMENT OF PATIENTS WITH PRIMARY HYPERCHOLESTEROLAEMIAInternational Journal Of Clinical Practice, 1999
- Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol LevelsJAMA, 1998
- The rule of 5 and the rule of 7 in lipid-lowering by statin drugsThe American Journal of Cardiology, 1997
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Women and Men with Hypercholesterolemia Respond Similarly to an American Heart Association Step 1 DietJournal of the American Dietetic Association, 1995
- The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association.Circulation, 1990
- SERUM CHOLESTEROL, BLOOD PRESSURE, AND MORTALITY: IMPLICATIONS FROM A COHORT OF 361 662 MENThe Lancet, 1986
- Epidemiology of coronary heart disease: The Framingham studyThe American Journal of Medicine, 1984